0000950103-24-001047.txt : 20240124 0000950103-24-001047.hdr.sgml : 20240124 20240124080036 ACCESSION NUMBER: 0000950103-24-001047 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240118 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADC Therapeutics SA CENTRAL INDEX KEY: 0001771910 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39071 FILM NUMBER: 24554279 BUSINESS ADDRESS: STREET 1: BIOPOLE STREET 2: ROUTE DE LA CORNICHE 3B CITY: EPALINGES STATE: V8 ZIP: 1066 BUSINESS PHONE: 41 21 653 02 00 MAIL ADDRESS: STREET 1: BIOPOLE STREET 2: ROUTE DE LA CORNICHE 3B CITY: EPALINGES STATE: V8 ZIP: 1066 8-K 1 dp205528_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 18, 2024

ADC Therapeutics SA

(Exact Name of Registrant as Specified in Its Charter)

Switzerland

(State or Other Jurisdiction of Incorporation)

001-39071

(Commission File Number)

N/A

(IRS Employer Identification Number)

Biopôle

Route de la Corniche 3B

1066 Epalinges

Switzerland

(Address of Principal Executive Offices) (Zip Code)

+41 21 653 02 00

(Registrant’s Telephone Number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Shares, par value CHF 0.08 per share	ADCT	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On January 18, 2024, ADC Therapeutics SA (the “Company”) entered into an agreement (the “Redmile Agreement”) with the Redmile Group, LLC (“Redmile”) regarding preemptive rights and advance subscription rights with respect to shares of the Company. The Company agreed that the Company’s board of directors will not restrict the preemptive rights of Redmile or its affiliates based on Article 4a(4)(g) of the Company’s articles of association or restrict the advance subscription rights of Redmile or its affiliates based on Article 4c(3) of the Company’s articles of association as long as (i) Redmile (including its affiliates and any other person or entity forming a “group” (as defined in Rule 13d-5 under the Exchange Act)) does not directly or indirectly control, own or have the right to control or own, collectively, shares representing more than 20% of the Company’s share capital or (ii) Redmile (including its affiliates and any other person or entity forming a “group” (as defined in Rule 13d-5 under the Exchange Act)) directly or indirectly controls, owns or has the right to control or own, collectively, shares representing more than 20% of the Company’s share capital but the Company’s board of directors determines that Redmile does not have an intent to effect a change of control of the Company. If, at any time, Redmile (including its affiliates and any other person or entity forming a “group” (as defined in Rule 13d-5 under the Exchange Act)) directly or indirectly controls, owns or has the right to control or own, collectively, shares representing more than 20% of the Company’s share capital and the Company’s board of directors determines that Redmile has an intent to effect a change of control of the Company, the Company’s board of directors will provide a reasonable opportunity to Redmile to explain its intentions. Thereafter, if the Company’s board of directors determines that Redmile does not intend to effect a change of control of the Company, the Company’s board of directors will not restrict the preemptive rights of Redmile or its affiliates based on Article 4a(4)(g) of the Company’s articles of association or restrict the advance subscription rights of Redmile or its affiliates based on Article 4c(3) of the Company’s articles of association. However, if the Company’s board of directors maintains its determination that Redmile has an intent to effect a change of control of the Company, the Company’s board of directors may restrict the preemptive rights of Redmile and its affiliates based on Article 4a(4)(g) of the Company’s articles of association and restrict the advance subscription rights of Redmile and its affiliates based on Article 4c(3) of the Company’s articles of association. The Redmile Agreement terminates upon the earliest of (i) the Company removing Article 4a(4)(g) and Article 4c(3) of the Company’s articles of association, (ii) after five years if Redmile and its affiliates directly or indirectly control, own or have the right to control or own, collectively, less than 20% of the Company’s share capital, (iii) the Company becomes incorporated in any state of the United States, (iv) Redmile (including its affiliates and any other person or entity forming a “group” (as defined in Rule 13d-5 under the Exchange Act)) directly or indirectly controls, owns or has the right to control or own, collectively, shares representing more than 30% of the Company’s share capital, other than solely as a result of the Company’s action, and (v) the Company’s board of directors determines that Redmile has an intent to effect a change of control of the Company pursuant to the foregoing sentence.

The foregoing description of the Redmile Agreement is not complete and is qualified in its entirety by the Redmile Agreement, which is filed as Exhibit 10.1 hereto and incorporated by reference into this description.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
10.1	Letter Agreement, dated January 18, 2024, between ADC Therapeutics SA and Redmile LLC
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADC Therapeutics SA
Date: January 24, 2024
	By:	/s/ Peter J. Graham
	Name:	Peter J. Graham
	Title:	Chief Legal Officer

EX-10.1 2 dp205528_ex1001.htm EXHIBIT 10.1

Exhibit 10.1

Agreement

of 18 January 2024

between

ADC Therapeutics SA

Biopôle

Route de la Corniche 3 B

1066 Epalinges

Switzerland

Legal@adctherapeutics.com

“Company”

and

Redmile Group, LLC

One Letterman Drive, Suite D3-300

San Francisco, CA 94129

United States

Redmile_legal@redmilegrp.com

“Redmile”

Company and Redmile each a “Party” collectively the “Parties”

regarding

the pre-emptive and advance subscription rights with respect to the shares in the Company

Page
1 / 6

WHEREAS

A.

As of the date hereof, Redmile, through certain funds which Redmile manages (the "Funds"), currently controls common shares of the Company (the "Shares") representing approximately 18.93% of the share capital registered in the commercial register.

B.

The articles of association of the Company (the "Articles") provide in article 4a (4)(g) that in the event of an issue of Shares, the board of directors of the Company (the "Board") is authorized to withdraw or restrict pre-emptive rights of existing shareholders and to allocate such rights to third parties, the Company or any of its group companies following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 20% of the share capital registered in the commercial register without having submitted to all other shareholders a takeover offer recommended by the Board.

C.

Furthermore, the Articles provide in article 4c (3) that in the event of an issue of bonds, notes, options, warrants or other securities or contractual obligations of the Company with conversion, exchange, option, warrant or similar rights or obligations for the subscription of Shares (the "Financial Instruments") the Board shall be authorized to restrict or withdraw advance subscription rights of shareholders in connection with the issuance of Financial Instruments by the Company or one of its group companies following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 20% of the share capital registered in the commercial register without having submitted to all other shareholders a takeover offer recommended by the Board.

D.

Redmile has confirmed to the Company that, as of the date hereof, it currently has no intention of effecting a change of control of the Company.

E.

The Parties wish to agree on the principles based on which the Board may restrict the pre-emptive or advance subscription rights of Redmile and its affiliates (as defined in Rule 405 under the Securities Act) (collectively, including the Funds, the “Affiliates”).

NOW, THEREFORE, the Parties agree as follows:

1.

Granting of Pre-emptive Rights and Advance Subscription Rights

The Company agrees that as long as Redmile and its Affiliates, together with any other person or entity forming a “group” (as defined in Rule 13d-5 under the Exchange Act) with Redmile or any of its Affiliates (such persons and entities, together with Redmile and its Affiliates, the “Group”), do not directly or indirectly control, own or have the right to control or own (regardless of whether such right is exercisable immediately or only after the passage of time), collectively, Shares representing 20% of the share capital registered in the commercial register, the Board will not restrict the pre-emptive rights of Redmile or any of its Affiliates based on article 4a (4)(g) of the Articles nor restrict the advance subscription rights of Redmile or any of its Affiliates based on article 4c (3) of the Articles if another shareholder increases its shareholding in the Company to more than 20% of the share capital registered in the commercial register and, as a result, the company exercises such rights.

Furthermore, the Company agrees that if the Group, directly or indirectly controls, owns or has the right to control or own (regardless of whether such right is exercisable immediately or only after the passage of time), collectively, Shares representing more than 20% of the share capital registered in the commercial register, and the Board determines (in the exercise of its fiduciary duties) that the Group has no intention to effect a change of control of the Company, the Board will not restrict the pre-emptive rights of Redmile or any of its Affiliates based on article 4a (4)(g) of the Articles or the advance subscription rights of Redmile or any of its Affiliates based on article 4c (3) of the Articles.

2.

Information

2.1.

Redmile

Redmile agrees that it shall:

Page
2 / 6

a)

notify the Company promptly (but no later than two business days) upon becoming aware that the Group directly or indirectly controls, owns or has the right to control or own (regardless of whether such right is exercisable immediately or only after the passage of time), collectively, Shares representing more than 20% of the share capital registered in the commercial register,

b)

notify the Company promptly (but no later than two business days) upon becoming aware that the Group directly or indirectly controls, owns or has the right to control or own (regardless of whether such right is exercisable immediately or only after the passage of time), collectively, Shares representing more than 30% of the share capital registered in the commercial register, and

c)

upon request by the Company (which may be via email), promptly (but no later than two business days) inform the Company of the number of Shares that the Group directly or indirectly controls, owns or has the right to control or own (regardless of whether such right is exercisable immediately or only after the passage of time).

2.2.

The Company

The Company agrees that it shall, upon request by Redmile (which may be via email), promptly (but no later than two business days) inform Redmile of the total amount of share capital then-registered in the commercial register.

3.

Intent to Effect a Change of Control

If, at any time, the Group directly or indirectly controls, owns or has the right to control or own (regardless of whether such right is exercisable immediately or only after the passage of time), collectively, Shares representing more than 20% of the share capital registered in the commercial register and the Board determines (in the exercise of its fiduciary duties) that the Group has an intent to effect a change of control of the Company, the Company shall notify Redmile of the Board’s determination, following which Redmile shall be afforded a reasonable opportunity to explain its intentions to the Board. Without limitation, the Board may deem the Group’s controlling, owning or having the right to control or own (regardless of whether such right is exercisable immediately or only after the passage of time), directly or indirectly, Shares representing more than 30% of the Company's share capital registered in the commercial register as an intention by the Group to effect a change of control of the Company.

a)

If, following the explanation by Redmile, the Board determines (in the exercise of its fiduciary duties) that the Group has no intention to effect a change of control of the Company, the Board will not restrict the pre-emptive rights of Redmile or any of its Affiliates based on article 4a (4)(g) of the Articles or the advance subscription rights of Redmile or any of its Affiliates based on article 4c (3) of the Articles.

b)

If, following the explanation by Redmile (or if Redmile fails to explain its intentions to the Board within a reasonable amount of time (which, for avoidance of doubt, shall not be less than five business days) or Redmile states its intent to effect a change of control of the Company), the Board maintains (in the exercise of its fiduciary duties) its determination that the Group has an intent to effect a change of control of the Company, the Board can, but is not obligated to restrict the pre-emptive rights and/or the advance subscription rights of the Group based on article 4a (4)(g) or article 4c (3) of the Articles.

For the avoidance of doubt, so long as consistent with Board’s fiduciary duties, for purposes of the Board making any determinations under this Section 3, Redmile and its Affiliates’ exercise of their rights as a shareholder in the ordinary course of business on Company proposals (including, without limitation, the exercise of voting rights attached to its Shares at any meeting of shareholders at which Redmile and its Affiliates are able to vote in accordance with the Articles and the limitations contained therein, including article 6(3)) shall not constitute a reasonable intention by Redmile and its Affiliates to effect a change of control of the Company.

Page
3 / 6

4.

Registration as shareholder with and exercise of voting rights

Except as otherwise mutually agreed between the Company and Redmile, Redmile shall not, and shall cause the Group to not, directly or indirectly, formally, constructively or beneficially own, or otherwise control, or exercise, in each case including through Nominees (as defined in the Articles), collectively, voting rights with respect to more than 15% of the Company's share capital registered in the commercial register from time to time.

5.

Redomiciliation

Prior to a Redomiciliation (as defined below), the Company will use reasonable efforts to provide arrangements for Redmile and its Affiliates to exchange or convert, upon such Redomiciliation or within a reasonable time thereafter, their Shares exceeding 9.99% of outstanding Shares immediately after such Redomiciliation for the same amount of non-voting securities (including, without limitation, warrants or preferred shares) that include a 9.99% beneficial ownership blocker. For the purposes of this Agreement, “Redomiciliation”, with respect to the Company, means the Company becoming incorporated in any state of the United States or merging into a corporation incorporated in any state of the Unites States for the sole purpose of changing the Company’s domicile.

6.

General Provisions

6.1.

Amendments

This Agreement may only be modified or amended by a document duly signed by all Parties. Any provision contained in this Agreement may only be waived by a document duly signed by the Party waiving such provision.

6.2.

Termination

This Agreement shall automatically terminate and cease to be effective without further action upon the earlier of:

a)

if the Company removes the 20% clauses (article 4a (4)(g) and article 4c (3) of the Articles) from the Articles, or

b)

at any point on or after the fifth (5^th) anniversary of the date of the Agreement, Redmile and its Affiliates directly or indirectly controlling, owning or having the right to control or own, collectively, Shares representing less than 20% of the Company's share capital registered in the commercial register, or

c)

the consummation of a Redomiciliation, or

d)

the Group directly or indirectly controls, owns or has the right to control or own (regardless of whether such right is exercisable immediately or only after the passage of time), collectively, Shares representing more than 30% of the Company's share capital registered in the commercial register, other than, solely as a result of action by the Company (for example, a share repurchase or an inaccuracy in the information provided by the Company to Redmile in section 2.2 hereof), or

e)

the Board determining, pursuant to section 3(b) hereof, that the Group has an intent to effect a change of control.

6.3.

Notices

All notices or other communications to be given under or in connection with this Agreement shall be made in writing and shall be delivered by e-mail to the addresses mentioned on the cover page of this Agreement.

Page
4 / 6

6.4.

Severability / Good Faith

Should any part or provision of this Agreement be held to be invalid by any competent court, governmental or administrative authority having jurisdiction, the other provisions of this Agreement shall nonetheless remain valid. In this case, the Parties shall endeavour to negotiate a substitute provision that best reflects the economic intentions of the Parties without being unenforceable, and shall execute all agreements and documents required in this connection. The same shall apply if and to the extent that this Agreement is found to contain any gaps or omissions.

6.5.

No Waiver

The failure of any of the Parties to enforce any of the provisions of this Agreement or any rights with respect thereto shall in no way be considered as a waiver of such provisions or rights or in any way affect the validity of this Agreement.

6.6.

No Assignment

Except as otherwise provided for in this Agreement, the Parties shall not assign this Agreement or any rights hereunder to any third party without the prior written consent of the other Party.

7.

Governing Law and Jurisdiction

This Agreement shall be governed by and construed in accordance with the substantive laws of Switzerland, without regard to its conflicts of laws rules.

All disputes arising out of or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendment and termination, shall be resolved by the ordinary courts in the city of Zurich, Switzerland.

[signature page follows]

Page
5 / 6

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and effective as of the date first written above.

ADC Therapeutics SA


By:	/s/ Ameet Mallik
	Name: Ameet Mallik
	Title: CEO

Redmile Group, LLC

By:	/s/ Joshua Garcia
	Name: Joshua Garcia
	Title: Authorized Signatory

Page
6 / 6

EX-101.SCH 3 adct-20240118.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 adct-20240118_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 adct-20240118_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 18, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 18, 2024
Entity File Number	001-39071
Entity Registrant Name	ADC Therapeutics SA
Entity Central Index Key	0001771910
Entity Tax Identification Number	00-0000000
Entity Incorporation, State or Country Code	V8
Entity Address, Address Line One	Biopôle
Entity Address, Address Line Two	Route de la Corniche 3B
Entity Address, City or Town	Epalinges
Entity Address, Country	CH
Entity Address, Postal Zip Code	1066
Country Region	41
City Area Code	21
Local Phone Number	653 02 00
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, par value CHF 0.08 per share
Trading Symbol	ADCT
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

XML 7 dp205528_8k_htm.xml IDEA: XBRL DOCUMENT 0001771910 2024-01-18 2024-01-18 iso4217:USD shares iso4217:USD shares false 0001771910 00-0000000 8-K 2024-01-18 ADC Therapeutics SA V8 001-39071 Biopôle Route de la Corniche 3B 1066 Epalinges CH 41 21 653 02 00 false false false false Common Shares, par value CHF 0.08 per share ADCT NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adctherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports adct-20240118.xsd adct-20240118_lab.xml adct-20240118_pre.xml dp205528_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dp205528_8k.htm": { "nsprefix": "ADCT", "nsuri": "http://adctherapeutics.com/20240118", "dts": { "schema": { "local": [ "adct-20240118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "adct-20240118_lab.xml" ] }, "presentationLink": { "local": [ "adct-20240118_pre.xml" ] }, "inline": { "local": [ "dp205528_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://adctherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dp205528_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dp205528_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950103-24-001047-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950103-24-001047-xbrl.zip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end